Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D08HPZ
|
||||
| Former ID |
DAP001448
|
||||
| Drug Name |
Tocilizumab
|
||||
| Synonyms |
Actemra; Actemra (TN); Tocilizumab (genetical recombination); Tocilizumab (USAN/INN); Tocilizumab (genetical recombination) (JAN)
|
||||
| Drug Type |
Monoclonal antibody
|
||||
| Indication | Rheumatoid arthritis [ICD9: 710-719, 714; ICD10:M05-M06] | Approved | [1], [2] | ||
| Juvenile idiopathic arthritis [ICD9: 714.3; ICD10:M08.0] | Phase 3 | [1], [2] | |||
| Company |
Roche; Genentech
|
||||
| CAS Number |
CAS 375823-41-9
|
||||
| PubChem Substance ID | |||||
| SuperDrug ATC ID |
L04AC07
|
||||
| Target and Pathway | |||||
| Target(s) | Interleukin-6 receptor | Target Info | Modulator | [3] | |
| KEGG Pathway | Cytokine-cytokine receptor interaction | ||||
| HIF-1 signaling pathway | |||||
| PI3K-Akt signaling pathway | |||||
| Jak-STAT signaling pathway | |||||
| Hematopoietic cell lineage | |||||
| Non-alcoholic fatty liver disease (NAFLD) | |||||
| Reactome | MAPK3 (ERK1) activation | ||||
| MAPK1 (ERK2) activation | |||||
| WikiPathways | SIDS Susceptibility Pathways | ||||
| Senescence and Autophagy in Cancer | |||||
| IL-6 signaling pathway | |||||
| Differentiation Pathway | |||||
| Interleukin-6 signaling | |||||
| References | |||||
| REF 1 | Molecular targets of rheumatoid arthritis. Inflamm Allergy Drug Targets. 2008 Mar;7(1):53-66. | ||||
| REF 2 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6881). | ||||
| REF 3 | Mullard A: 2010 FDA drug approvals. Nat Rev Drug Discov. 2011 Feb;10(2):82-5. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.